Cargando…
Clinical outcomes based on multigene profiling in metastatic breast cancer patients
BACKGROUND: Identifying the clinical impact of recurrent mutations can help define their role in cancer. Here, we identify frequent hotspot mutations in metastatic breast cancer (MBC) patients and associate them with clinical outcomes. PATIENTS AND METHODS: Hotspot mutation testing was conducted in...
Autores principales: | Basho, Reva K., de Melo Gagliato, Debora, Ueno, Naoto T., Wathoo, Chetna, Chen, Huiqin, Shariati, Maryam, Wei, Caimiao, Alvarez, Ricardo H., Moulder, Stacy L., Sahin, Aysegul A., Roy-Chowdhuri, Sinchita, Chavez-MacGregor, Mariana, Litton, Jennifer K., Valero, Vincent, Luthra, Raja, Zeng, Jia, Shaw, Kenna R., Mendelsohn, John, Mills, Gordon B., Tripathy, Debu, Meric-Bernstam, Funda |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5363515/ https://www.ncbi.nlm.nih.gov/pubmed/27806348 http://dx.doi.org/10.18632/oncotarget.12987 |
Ejemplares similares
-
Somatic mutations, clinicopathologic characteristics, and survival in patients with untreated breast cancer with bone-only and non-bone sites of first metastasis
por: Kono, Miho, et al.
Publicado: (2018) -
Functional consequence of the MET-T1010I polymorphism in breast cancer
por: Liu, Shuying, et al.
Publicado: (2014) -
A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory
por: Arango, Natalia Paez, et al.
Publicado: (2017) -
Emergence of mTOR mutation as an acquired resistance mechanism to AKT inhibition, and subsequent response to mTORC1/2 inhibition
por: Coleman, Niamh, et al.
Publicado: (2021) -
The transfer of multigene panel testing for hereditary breast and ovarian cancer to healthcare: What are the implications for the management of patients and families?
por: Eliade, Marie, et al.
Publicado: (2016)